title: Implementation of a standardized protocol for prevention and management of oral mucositis in patients undergoing hematopoietic cell transplantation.
abstract: OBJECTIVE
  Oral mucositis is a serious problem that affects a significant number of hematopoietic cell transplant (HCT) patients. There are many gaps in management, and evidence-based guidelines do not provide consistent recommendations. The purpose of this pilot study was to develop a mucositis oral care protocol for the prevention and management of mucositis in the HCT patient and to evaluate the clinical impact of its implementation.
  
  
  METHODS
  After receipt of Institutional Review Board approval, all patients admitted to the Hematology-Oncology service for high-dose chemotherapy followed by an autologous or allogeneic HCT were eligible for the study. As part of a change in practice, a new mucositis protocol consisting of a specific oral care regimen was instituted for prevention and treatment of mucositis. Assessment of mucositis began upon admission to the hospital and the patient was evaluated using a mucositis grading scale on a daily basis by the physician and nursing staff. The new mucositis protocol was a part of the HCT service admission orders for each patient. The group of patients treated according to the new mucositis protocol were compared with a retrospective control group consisting of patients who had undergone management of oral mucositis under the previous standard of care. The primary endpoints were to evaluate incidence, severity, and duration of oral mucositis. Secondary endpoints included days requiring narcotics; days of parenteral nutrition, febrile neutropenia, antimicrobial therapy, and length of hospital stay.
  
  
  RESULTS
  There were 13 patients enrolled in the control group and 12 patients in the new protocol group. The new protocol resulted in a decreased incidence (100% vs. 75%) and duration (19.2 vs. 8.3 days) of mucositis. Days of maximum grade one and three mucositis were decreased by 56%, and 70%, respectively. Days of maximum grade two mucositis, however increased by 22%. The days of narcotic use were reduced by 19% in the new protocol group (15.8 vs. 12.8 days). All patients in the new protocol group required parenteral nutrition, but days of use were reduced by 41% (17 vs. 10.2 days). The incidence of infection measured by days of febrile neutropenia and antimicrobial therapy were reduced by 35% (10.2 vs. 6.5 days) and 33% (17 vs. 11.4 days). Finally, the overall length of hospital stay was reduced by 7 days (30 vs. 23 days).
  
  
  CONCLUSIONS
  Implementation of a standardized oral care protocol for mucositis management resulted in a decreased incidence, duration and severity of mucositis, and also reduced the global negative impact of mucositis. Future studies may further evaluate the global impact by adjusting for confounding factors.
authors.affiliation: Department of Pharmacy, Mayo Clinic Florida, Jacksonville, FL, USA. Bhattv@mskcc.org
authors.forename: Valkal
authors.initials: V
authors.lastname: Bhatt
authors.forename: Nancy
authors.initials: N
authors.lastname: Vendrell
authors.forename: Karen
authors.initials: K
authors.lastname: Nau
authors.forename: Deborah
authors.initials: D
authors.lastname: Crumb
authors.forename: Vivek
authors.initials: V
authors.lastname: Roy
mesh_terms: D000891:Anti-Infective Agents, Local / Q000627:therapeutic use; D000935:Antifungal Agents / Q000627:therapeutic use; D002985:Clinical Protocols / Q000592:standards*; D017679:Cryotherapy; D005260:Female; D051523:Fibroblast Growth Factor 7 / Q000627:therapeutic use; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects*; D006801:Humans; D007902:Length of Stay; D008297:Male; D008875:Middle Aged; D009067:Mouthwashes / Q000627:therapeutic use; D052016:Mucositis / Q000209:etiology / Q000517:prevention & control*; D010865:Pilot Projects; D011446:Prospective Studies; D012189:Retrospective Studies; D059039:Standard of Care / Q000458:organization & administration*
chemical_list: D000891:Anti-Infective Agents, Local; D000935:Antifungal Agents; D009067:Mouthwashes; D051523:Fibroblast Growth Factor 7